Skip to main content
. Author manuscript; available in PMC: 2023 Jun 16.
Published in final edited form as: Cancer Res. 2022 Dec 16;82(24):4624–4640. doi: 10.1158/0008-5472.CAN-22-0736

Figure 8. Model depicting the function of PRC2-catalyzed H3K27me3 in inactivating type I IFN-STAT2 axis in luminal breast cancer.

Figure 8.

Pharmacological inhibition of PRC2 complex (EZH2i) releases the epigenetic silencing of genes encoding type I IFN ligands, induces an autocrine activation of the IFN signaling mediated by STAT2 and subsequently generates an antitumor microenvironment in ERα+ breast cancer (BCa) cells.